Mavicampton in Patients With Obstructive Hypertrophic Cardiomyopathy

The valor HCM trial was another important first at ACC22. Mavicampton is an agent that reduces cardiac muscle contractility. It inhibits the excessive myosin-acting cross-bridge information in cardiac myocytes. This really is the first pharmacotherapy that offers a viable medical option for people with obstructive hypertrophic cardiomyopathy short of needing an invasive procedure.